Article
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Annals of hematology - 1 Oct 2023
Cremer Anjali, Enssle Julius C, Pfaff Saskia, Kouidri Khouloud, Lang Fabian, Brandts Christian, Zeiher Andreas, Cremer Sebastian, Steffen Björn, Serve Hubert, Bug Gesine
Abstract excerpt
The addition of midostaurin to standard chemotherapy has improved survival in patients with FLT3-mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell transplantation in a real-world setting. We reviewed 132 patients with AML who were treated with intensive...
Topics
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Staurosporine
- Protein Kinase Inhibitors
- Hematopoietic Stem Cell Transplantation
- fms-Like Tyrosine Kinase 3